Source - RNS
RNS Number : 4876T
Integumen PLC
21 March 2019
 

AIM share code: SKIN

 

21 March 2019

Integumen PLC

("Integumen" or "Company")

 

Exercise of Warrants

 

Integumen, the AIM-quoted announces that it has received notification from a warrant holder to exercise warrants over 2,000,000 shares of 0.01p each in the share capital of Integumen ("New Ordinary Shares"). The consideration for the exercise of the warrants  amounts, in aggregate, to a cash value of £30,000.

 

The Warrant holder holds a further 6,333,332 warrants priced at 1.5p expiring January 2021. The New Ordinary Shares have been allotted, and application has been made for admission to trading on AIM ("Admission") for the New Ordinary Shares. Admission is expected  on or about 26 March 2019. The New Ordinary Shares will rank pari passu with the ordinary shares of the Company in issue.

 

Total voting rights

 

The Company's total issued capital, after the issue of the New Ordinary Shares, will be 476,450,802 ordinary shares. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.

 

Contacts

 

Integumen plc

Gerard Brandon, CEO

 

+44 (0) 7340 055 643

SPARK Advisory Partners Limited

(Nominated Adviser)

 

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Hybridan LLP  (Broker)

Claire Noyce

+44 (0) 20 3764 2341

 

About Integumen:

 

Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

 

The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCSEWFISFUSEFD